Find a Clinical Trial

Showing 61 - 70 of 180 Trials

  • A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patientswith Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 GeneAlterations (NePtune)

    Principal Investigator:

    Karie Danielle Keera Runcie, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05498272

    Population:

    Adult

    Phase:

    II
    This is a research study to find out if giving a drug called olaparib with a Luteinizing hormone- releasing hormone (LHRH) agonist (medication that suppresses testosterone) before you undergo a radical prostatectomy (surgery to remove your prostate) decreases the amount of cancer present at the time of surgery and decrease the risk of the disease coming back after surgery. You will receive one of the LHRH agonist: leuprolide, triptorelin or goserelin. Olaparib, leuprolide, triptorelin and goserelin is FDA approved for several types of cancers such as certain types of ovarian, breast,...

  • A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB1305 inParticipants with Advanced/Metastatic Solid Tumors

    Principal Investigator:

    Brian Henick, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06953089

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to test whether combining two investigational study drugs, DB-1311 with BNT327 or DB-1311 with DB-1305, is safe and can be tolerated by participants with advanced or metastatic solid tumors. The study will also test how much of the study drugs are in the blood at different times, if the body makes antibodies against the study drugs, and how the study drugs affect the disease. Additionally, the study may also explore how certain molecules in the blood or tissue (biomarkers) relate to the drug's effects. DB-1311, BNT327, and DB-1305 are investigational drugs,...

  • A Phase 2 Multicenter Study of TL-895 in Subjects withMyelofibrosis, Indolent Systemic Mastocytosis, MonoclonalMast Cell Activation Syndrome, or Non-Monoclonal Mast CellActivation Syndrome

    Principal Investigator:

    Joseph G. Jurcic, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04655118

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to evaluate whether the investigational drug TL-895, which has not been approved by the U.S. Food and Drug Administration (FDA), can help improve symptoms in people with indolent systemic mastocytosis (ISM). TL-895 is being studied alone, in combination with avapritinib, and in comparison with either placebo or avapritinib. Avapritinib is an approved drug that is already used to treat certain types of systemic mastocytosis. A placebo is a treatment with no active therapeutic effect, used to compare against an investigational drug. The main goals of the study are...

  • A Phase 3, multicenter, clinical study to evaluate the efficacy and safety of safusidenib erbumine in participants with isocitrate dehydrogenase 1 (IDH1)-mutant glioma

    Principal Investigator:

    Andrew B. Lassman, MD, FAAN, FASCO

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05303519

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to see how safe and effective Safusidenib erbumine, the study drug, is in treating brain glioma and to find the recommended dose of the study drug for clinical studies. Safusidenib is not Food and Drug Administration (FDA) approved. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Must have have life expectancy 3 months or more - Must have negative result for COVID

  • Chemo4METPANC - A Phase 2 study with combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (Motixafortide), and immune checkpoint blockade (Cemiplimab) in METastatic treatment naïve PANCreas

    Principal Investigator:

    Gulam A. Manji, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04543071

    Population:

    Adult

    Phase:

    II
    You are being invited to take part in this research study because you have been diagnosed with pancreas cancer that has spread to other parts of the body. The purpose of this study is to determine if combination treatment with cemiplimab, motixafortide, gemcitabine, and nab-paclitaxel is effective in decreasing tumor size and prolonging life in patients with advanced pancreas cancer. The treatment consists of both immunotherapy (cemiplimab and motixafortide) and chemotherapy (gemcitabine and nab-paclitaxel). Gemcitabine and nab-paclitaxel are approved by the Food and Drug Administration (FDA...

  • Cascade Testing In Racially/Ethnically Diverse Relatives of Patients with Breast or Ovarian Cancer (CASSIE)

    Principal Investigator:

    Alissa Michel, MD

    Contact Number:

    212-342-5162

    Population:

    Adult

    Phase:

    II
    The study is being done to answer the following question: How can we best help women with family members who have cancer and a genetic mutation in a cancer gene make decisions about undergoing genetic testing? We are doing this study because we want to better understand if our web-based tool, RealRisks, can help women with family members who have a genetic variant make an informed decision about genetic testing. Are you Eligible? (Inclusion Criteria) 18 years or older. - Both men and women of all races and ethnic groups are eligible as probands for this trial. Only female first-degree...

  • Defining the role of ctDNA monitoring in a novel, risk stratified clinical trial for PTLD.

    Principal Investigator:

    Jennifer Effie Amengual, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06954805

    Population:

    Pediatrics/Adult

    Phase:

    II
    The purpose of this study is to find out if there is a benefit to giving rituximab with etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (R-EPOCH) in patients who have high-risk Bcell posttransplant lymphoproliferative disorder (PTLD), while those with low-risk disease will be spared of chemotherapy and treated with rituximab alone. Concurrently this study also wants to see how helpful a new blood test called circulating tumor DNA (ctDNA) is. This test has already helped doctors make better predictions and treatment decisions in other types of lymphoma. The goal is to...

  • EXACT: Randomized phase II trial of XL092 in combination with immunotherapy in patients who progress on Adjuvant therapy in Clear Cell RCC

    Principal Investigator:

    Karie Danielle Keera Runcie, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT06863311

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to see if study drug XL092 alone or in combination with nivolumab can treat your cancer after your cancer has progressed on adjuvant treatment. Researchers also want to look at the safety of the XL092 alone and in combination with nivolumab. We are asking you to take part in this research study because you have clear cell renal cell carcinoma (clear cell kidney cancer), and your disease has come back after adjuvant treatment (treatment given after your disease progresses from your first treatment). - XL092 is not approved by the U.S. Food and Drug Administration (...

  • Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2

    Principal Investigator:

    Meghna S Trivedi, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT01042379

    Population:

    Adult

    Phase:

    II
    The primary purpose of this trial is to determine whether adding new drugs to the standard initial cancer treatments for breast cancer increases the probability there there will be no residual disease (cancer cells left after many attempts to remove the cancer), compared to the initial cancer treatment alone. The intervention includes different drugs to determine which study drugs might result in better outcomes than standard treatment. Are you Eligible? (Inclusion Criteria) To be eligible for this trial patients must: have breast cancer and cannot already have had chemotherapy. be at least...

  • MRD-GUIDED SEQUENTIAL THERAPY FOR DEEP RESPONSE IN NEWLY DIAGNOSED MULTIPLE MYELOMA - MASTER-2 TRIAL

    Principal Investigator:

    Rajshekhar Chakraborty, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05231629

    Population:

    Adult

    Phase:

    II
    The purpose of the study is to determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is multiple myeloma cells below the level of 1 cancer cell out of 100,000 in the bone marrow. For patients who are MRD “positive” at the end of 6 cycles of therapy, this study will answer whether more patients can become and remain MRD “negative” with autologous hematopoietic cell transplantation (AHCT) plus a new immunotherapy called teclistamab in combination with...

Pages

Back to top